News and Media

Therapeutic solutions ensure good control of cardiovascular diseases and increase patients’ quality of life

According to the data of the National Health Insurance Fund for the third quarter of the last year, Tchaikapharma’s medicinal product “Zornichka” with active ingredient (INN) chlorthalidone marked an increase in the number of packages sold by nearly 95% (compared to the same period in 2023), reaching 40 thousand packages. “Zornicka” belongs to a group of medicines called thiazide diuretics (“dehydrating tablets”).

“Doxazosin-Tchaikapharma also ranks among the top performers with the largest market share in the group of so-called “alpha blockers” used to treat high blood pressure (hypertension) or symptoms due to an enlargement of the prostate gland (benign prostatic hyperplasia ) with more than 62 thousand packs sold.

The huge palette of nearly 50 medicinal products manufactured by Tchaikapharma High Quality Medicines Inc. for the treatment of cardiovascular diseases guarantees a wide therapeutic choice for specialists in the treatment of hypertension, atherosclerosis, dyslipidemias, heart attacks, thrombosis and coronary artery disease. For years, cardiovascular disease has been the number one cause of death in Bulgaria and has been identified as one of the most socially significant diseases due to its high rate of disability and reduced work capacity. For 25 years Tchaikapharma has been improving the quality of life of Bulgarian families by providing affordable modern therapeutic solutions.

Once again, Tchaikapharma High Quality Medicines participated in the National Conference on Hospital Pharmacy held in Sofia from 18-20 October 2024. The leading Bulgarian manufacturer of complex generics (polypills) presented its new products for the treatment of socially significant diseases such as cerebrovascular disease, Parkinson’s disease, impaired metabolic syndrome, angina pectoris, arterial hypertension and heart failure. The stable supply chains established over the years and modern production conditions complying with the highest European standards guarantee continuity of therapeutic intake for Bulgarian and European patients.

The conference, organized by the Bulgarian Association of Hospital and Clinical Pharmacists, was held for the eighteenth consecutive year. It brought together representatives of the leading pharmaceutical companies as well as Master Pharmacists from all over the country.

Tchaikapharma has received marketing authorization for a new medicinal product:

Telmira 60 mg film-coated tablets
Telmira 90 mg film-coated tablets

Telmira contains a medicinal substance called ticagrelor. It belongs to a group of medicines called antithrombotic medicines.

Telmira, given at the same time as acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with:

– acute coronary syndrome (ACS) or

– a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.

The medicinal product is available on prescription.
ATC code: B01AC24

The latest medicinal product to receive Marketing Authorisation from the Bulgarian Drug Agency is:

Ferbessa 4 mg/5 mg tablets

Ferbessa 8 mg/5 mg tablets

Ferbessa is a combination of the two active substances: perindopril and amlodipine. Perindopril is an angiotensin-converting enzyme inhibitor (ACE inhibitor). Amlodipine is a calcium antagonist that belongs to a class of drugs called dihydropyridines.

Together, they help blood vessels to dilate and relax so that blood flows more easily through them and makes it easier for the heart to maintain good blood flow.

Ferbessa is indicated as replacement therapy for the treatment of essential hypertension and/or stable coronary artery disease in patients previously controlled with perindopril and amlodipine taken alternatively at the same dosage. The fixed combination is not suitable for initial treatment.

The medicinal product is available on prescription.

ATC code: C09BB04

mag. pharma. Silvia Patrikova, Director of ‘Pharmaceutical Care’ and Member of the Board of Directors of Tchaikapharma High Quality Medicines

Nearly two years after the peak of the COVID-19 pandemic, the global pharmaceutical market is suffering from chaos in supply chains and unpredictable dynamics in demand for individual products. It is difficult to guarantee patients access to their prescribed therapy. Our country is also in the grip of these trends. News of missing medicines in pharmacies and hospitals has become a daily occurrence. In these conditions of market stress, Tchaikapharma High Quality Medicines (Tchaikapharma), formerly known as ‘High Quality Medicines Available to Everyone’, has been able to preserve its critical supply lines and secure new avenues to maintain a continuous and seamless manufacturing process.

This ensured availability and achieved continuity of therapeutic intake for all our patients. The high class of guaranteed pharmaceutical care has given their physicians new confidence that they can continue to rely on Tchaikapharma, which they know well, as a trusted manufacturer and partner in their daily choice of complex generic medicines. Compounded medications (complex generics) are “the future of pharmaceutical care,” as former FDA Director General – Scott Gottlieb used to say. In these, two or three drugs with complementary therapeutic effects are combined into a single dosage form, guaranteeing the duration of the prescribed therapy and optimising costs for both public resources and patients.

At the height of the pandemic, Tchaikapharma was “in the eye of the storm” especially when, in moments of desperation, the state had no alternative supplier of antibiotics for hospital intensive care units and foreign manufacturers were locked in the selfish grip of their governments. The lives of thousands of patients were saved thanks to our continuous work, seven days a week, for 5 months – and the entire management of the leading Bulgarian manufacturer was constantly engaged in ensuring production and patient access to the necessary therapy.

We don’t get giddy about the prestige gained over the years or the new successes – the focus is always on the upcoming projects. Tchaikapharma’s highly recognizable brand, goodwill and reputation oblige us to seek and provide direct generic and/or therapeutic alternatives for the treatment of socially important diseases such as cerebrovascular disease, Parkinson’s disease, impaired metabolic syndrome, angina pectoris, hypertension and heart failure. It is not easy to provide alternatives in a short timeframe to the out-of-stock or limited-availability therapies included in the List of Medicinal Products under Article 217c of the MHPAA generated by the Specialised Electronic System for the Tracking and Analysis of Medicinal Products (CESPA). Of course, stable supply chains ensuring continuity of the manufacturing process gives us the freedom to focus our resources on the development of new pharmaceutical forms. We are constantly working on expanding the therapeutic use of the drugs on the product list, which has been continuously supplemented for the second year with new capsule forms – whose efficacy is widely preferred in the oral group.

Now, Tchaikapharma is fully prepared for the new autumn-winter season, characterized by increased incidence of respiratory viruses and a gradually rising number of new cases of COVID. The Bulgarian pharmaceutical manufacturer has upgraded its antibiotic production infrastructure and successfully implemented new working practices in line with increased clean production standards.

A national leader in widely available generic medicines, our company is preferred by investors and savers and has shown remarkable stability as the market capitalization leader on the Bulgarian Stock Exchange for the eighth consecutive year.